Page last updated: 2024-11-13
leukotriene c4 monomethyl ester
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
leukotriene C4 monomethyl ester: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
leukotriene C4 methyl ester : The methyl ester of leukotriene C4, the esterified acid group being the one forming position 1 of the icosatetraenyl chain. Leukotriene C4 methyl ester is a more lipid-soluble form of leukotriene C4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 101070933 |
CHEBI ID | 138115 |
MeSH ID | M0126927 |
Synonyms (17)
Synonym |
---|
leukotriene c4 monomethyl ester |
leukotriene c4 methyl ester |
l-gamma-glutamyl-s-[(5s,6r,7e,9e,11z,14z)-5-hydroxy-1-methoxy-1-oxoicosa-7,9,11,14-tetraen-6-yl]-l-cysteinylglycine |
73958-10-8 |
ltc4, methyl ester |
(2s)-2-amino-5-{[(2r)-1-[(carboxymethyl)amino]-3-{[(5s,6r,7e,9e,11z,14z)-5-hydroxy-1-methoxy-1-oxoicosa-7,9,11,14-tetraen-6-yl]sulfanyl}-1-oxopropan-2-yl]amino}-5-oxopentanoic acid |
CHEBI:138115 |
n-methyl-ltc4 |
ltc4 me |
glycine, n-(n-l-gamma-glutamyl-s-(1-(1-hydroxy-5-methoxy-5-oxopentyl)-2,4,6,9-pentadecatetraenyl)-l-cysteinyl)-, (r-(r*,s*-(e,e,z,z)))- |
n-methyl-leukotriene c4 |
leukotriene c methyl ester |
n5-((r)-1-((carboxymethyl)amino)-3-(((5s,6r,7e,9e,11z,14z)-5-hydroxy-1-methoxy-1-oxoicosa-7,9,11,14-tetraen-6-yl)thio)-1-oxopropan-2-yl)-l-glutamine |
(2s)-2-amino-5-[[(2r)-1-(carboxymethylamino)-3-[(5s,6r,7e,9e,11z,14z)-5-hydroxy-1-methoxy-1-oxoicosa-7,9,11,14-tetraen-6-yl]sulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid |
l-gamma-glutamyl-s-[(1r,2e,4e,6z,9z)-1-[(1s)-1-hydroxy-5-methoxy-5-oxopentyl]-2,4,6,9-pentadecatetraen-1-yl]-l-cysteinylglycine |
DTXSID901104248 |
AKOS040755941 |
Research Excerpts
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" In this study, the dose-response curves of N-methyl LTC4 (NMLTC4), the nonmetabolizable LTC4 analogue, and the peptidoleukotrienes (LTC4, LTD4, and LTE4) were obtained in the absence and presence of the leukotriene antagonist Ro 23-3544 in cannulated frogs." | ( Cardiovascular effects of N-methyl leukotriene C4, a nonmetabolizable leukotriene C4 analogue, and the antagonism of leukotriene-induced hypotension by Ro 23-3544, in the American bullfrog, Rana catesbeiana. Herman, CA; Sun, J, 1995) | 0.29 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (2)
Class | Description |
---|---|
methyl ester | Any carboxylic ester resulting from the formal condensation of a carboxy group with methanol. |
leukotriene | Any icosanoid from that family of C20 polyunsaturated fatty acids and their derivatives generated by leukocytes from arachidonic acid, each member having four double bonds of which three are conjugated. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (7)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (28.57) | 18.7374 |
1990's | 4 (57.14) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (14.29) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |